Mission Wealth Management LP Purchases 19 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mission Wealth Management LP boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 471 shares of the biopharmaceutical company’s stock after buying an additional 19 shares during the quarter. Mission Wealth Management LP’s holdings in Regeneron Pharmaceuticals were worth $414,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in REGN. Meyer Handelman Co. boosted its holdings in Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after buying an additional 435 shares during the last quarter. Stifel Financial Corp lifted its holdings in Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after acquiring an additional 3,385 shares in the last quarter. LPL Financial LLC lifted its holdings in Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after acquiring an additional 3,479 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after acquiring an additional 1,221 shares during the period. Finally, Monetary Management Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 4.8% in the third quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock worth $901,000 after acquiring an additional 50 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $957.00 on Friday. The company has a current ratio of 6.40, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $944.24 and its 200-day moving average is $895.54. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The firm has a market cap of $105.04 billion, a P/E ratio of 28.27, a price-to-earnings-growth ratio of 2.69 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business’s revenue for the quarter was up .6% on a year-over-year basis. During the same period last year, the firm earned $10.96 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total transaction of $950,000.00. Following the sale, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at approximately $36,615,850. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph J. Larosa sold 1,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total value of $950,000.00. Following the sale, the executive vice president now owns 38,543 shares of the company’s stock, valued at $36,615,850. The disclosure for this sale can be found here. Insiders have sold a total of 10,095 shares of company stock worth $9,664,476 in the last 90 days. Company insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on REGN shares. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. UBS Group increased their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.